Objective: The human cytidine deaminase APOBEC3G (A3G) potently restricts HIV-1 but the virus, in turn, expresses a Vif protein which degrades A3G. A natural A3G-H186R variant, common in African populations, has been associated with a more rapid AIDS disease progression, but the underlying mechanism remains unknown. We hypothesized that differences in HIV-1 Vif activity towards A3G wild type and A3G-H186R contribute to the distinct clinical AIDS manifestation.
Introduction
Successful HIV-1 replication in the host depends on its ability to evade a myriad of innate and adaptive immune defences [1] [2] [3] [4] [5] [6] [7] . Among the innate immune factors that exert pressure on HIV-1 are host restriction factors such as the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G protein (APO-BEC3G, A3G), which belongs to the family of cytidine deaminases [8, 9] . A3G inhibits HIV-1 replication by deaminating single stranded viral DNA during reverse transcription, resulting in guanine-to-adenine mutations across the proviral genome [8, 10, 11] . Deaminase-independent mechanisms of A3G restriction have also been described [12] [13] [14] [15] . HIV-1 viral infectivity factor protein, Vif, promotes the proteasomal degradation of A3G, allowing productive viral replication [16 -18] .
A natural A3G polymorphism H186R is frequent in African populations with minor allele frequencies ranging from 30% in South Africans [19] to between 25 and 51% in other African populations [20] . The polymorphism is rare in white (2-3%) and Asian (0-10%) populations [20] . This A3G-H186R variant has been associated with higher viral loads, decreased CD4 þ T-cell counts and a more rapid progression to AIDS in patients homozygous for A3G-H186R [19, [21] [22] [23] . However, other studies which mainly analysed the effect of the heterozygous A3G WT/H186R variant found no association with disease progression [24] [25] [26] [27] . Despite the clear correlation of A3G-H186R in vivo, the mechanism remains unknown [21, 28] .
We recently showed that HIV-1 Vif adapts to different APOBEC3H (A3H) haplotypes in HIV-1-infected patients [29] . However, it remains unknown whether A3G haplotypes similarly select for specific Vif variants. If a given A3G variant is more or less susceptible to HIV-1 Vif mediated degradation, it is conceivable that this altered viral host interaction could result in an altered HIV/AIDS disease presentation.
Of note, most Vif-A3G studies have focused on subtype B Vif variants, which only represent $10% of all global infections [30] . However, the greatest burden of infections is in sub-Saharan Africa where HIV-1 subtype C predominates [30] . Only two studies, including one from our group, functionally analysed a limited number of subtype C variants. Both studies concluded that subtype C Vif had similar or enhanced activity against wild type A3G as compared to subtype B Vifs. [31, 32] .
To our knowledge, the current study is the first to investigate the antiA3G phenotype of subtype C Vif alleles obtained from patients with distinct A3G haplotypes.
Materials and methods

Study participants
We selected 26 women from the 'Centre for the AIDS Programme of Research in South Africa' acute infection study (CAPRISA 002) in Durban, South Africa [33] based on the A3G genotype information that was previously determined [19] . Plasma viremia and CD4 þ T-cell counts are regularly documented, and samples are stored for future research. Participants provided written informed consent, and ethical approval was obtained from the Biomedical Research Ethics Committee of the University of KwaZulu-Natal.
We obtained plasma samples from 11 A3G WT/WT , 10 A3G WT/H186R and 5 A3G H186R/H186R chronically infected, antiretroviral therapy-naïve study participants. The plasma viremia and absolute CD4 þ T-cell counts were obtained approximately 36 months postinfection and were comparable between patients with different A3G haplotypes.
HIV-1 Vif amplification and cloning
Viral RNA was extracted from plasma using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and cDNA synthesized using Thermoscript RT PCR System (Invitrogen, ThermoFisher Scientific, Waltham, Massachusetts, USA). The HIV-1 Vif coding region was amplified by nested PCR with the Expand High Fidelity PCR System (Roche, Penzberg, Germany) using the primers Vif1-forward 5 0 AAAATTAGCAGGAAGAT GGCCAGT3 0 and Vif1-reverse 5 0 CTCCGCTTCTTC CTGCCATAGGAGAT3 0 , and Vif2-forward 5 0 TACTC TGGAAAGGTGAAGG3 0 and Vif2-reverse 5 0 CTTCC TGCCATAGGAGATGCCTAA3 0 . Five separate PCR reactions were performed per patient and gel-purified amplicons were cloned into the pCR2.1 TOPO cloning vector (Invitrogen). Two to four clones of each PCR were sequenced resulting in 10-20 sequences for each patient. The GenBank accession numbers for the vif sequences generated in this study are KT881902-KT882293.
Vif and A3G expression plasmids
One representative HIV-1 Vif variant from each of the 11 A3G WT/WT and 5 A3G H186R/H186R donors was selected for functional characterization. The Vif ORF was carboxy-terminal FLAG tagged and cloned into the mammalian expression plasmid pCRV1, as previously described [34, 35] . Carboxy-terminal haemagglutinintagged wild type A3G and A3G-H186R were cloned into the mammalian expression plasmid PTR600, as previously described [36] .
Cell culture TZM-bl cells were provided by J.C. Kappes and X. Wu through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health, NIH Reagent Program. HEK-293T and TZM-bl were maintained at 37 8C in a humidified atmosphere of 5% CO 2 in Dulbecco's high-glucose modified Eagle's medium (CellGro, Corning, New York, USA), supplemented with 10% foetal bovine serum and penicillin/streptomycin.
A3G degradation and single-cycle viral infectivity assays
HEK-293T cells were co-transfected with 500 ng of HIV pNL4-3Dvif, 50 ng of each Vif expression plasmid and 20 ng of wild type or A3G-H186R with 4 mg/ml of polyethylenimine, as previously described [36] . The replication-competent molecular clone NL4-3DVif was provided by the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health. After 48 h, viral supernatants were collected and the cells were lysed and analysed by western blot, as previously described [36] . Viral supernatants were used to infect TZM-bl cells, and b-galactosidase activity was measured 48 h postinfection, as previously described [29] .
Statistical analysis
GraphPad Prism version 5.01 was used for statistical analyses (paired and unpaired t tests). P values less than 0.05 were considered significant. Average relative infectivity values and their SDs were calculated from representative triplicate transfections.
Results
Phylogenetic analysis of Vif sequences
Despite the availability of HIV-1 subtype C vif sequences [37] [38] [39] , functional data regarding their antiA3G activity remains very limited [31, 32] . We therefore cloned, sequenced and analysed HIV-1 subtype C vif alleles from patients homozygous for wild type A3G, homozygous for A3G-H186R and from heterozygous patients [19] . We generated 392 full length HIV-1 subtype C vif clonal sequences. Phylogenetic analysis confirmed that all sequences were subtype C (data not shown) and vif clonal sequences from each patient clustered independently ( Fig. 1a ). Intrapatient sequences differed between 0.1 and 4.9% and interpatient diversity ranged from 6.2 to 19.2% at the protein level. We observed no significant correlations between intrapatient sequence diversity and viral loads or CD4 þ cell counts (data not shown).
An alignment of each patient's consensus sequences is shown in Fig. 1b . Putative sites of interaction with A3G or Cullin 5 and the E3 ubiquitin ligase complex are indicated by different colours (Fig. 1b) . The sites of potential interaction with A3G include amino acids at position 9, 22, 45 and 48 [34, 40] ; the YRHHY motif (40) (41) (42) (43) (44) [41] ; the VHIPLx4-5Lx2YWGL motif (positions 55-59, 64, 69-72) [42] ; tryptophans at Antiviral activity of natural APOBEC3G haplotypes Reddy et al. 1725 positions 5, 21, 38 and 89 [43] , were not different between sequences. Similarly, the HCCH and SLQYLA motifs, which are binding sites of Cullin 5 [44, 45] and Elongin C (144-149) were conserved [16, 46, 47] .
Phenotypic characterization of HIV subtype C Vif variants
There is evidence that natural Vif variants differ in their ability to neutralize A3G [31, 32, 34] , and we speculate that Vif diversity may emerge as it adapts to an individual's A3G repertoire. We functionally characterized the patient-derived subtype C Vif panel for A3G degradation and counteraction in single-cycle infectivity assays. We co-transfected HIVDVif with individual Vif expression plasmids, wild type A3G or A3G-H186R. HIV-1 infectivity was subsequently analysed by infecting TZM-bl reporter cells with viral supernatants, collected 2 days posttransfection. Infectivity values were plotted relative to HIV-1 in the absence of A3G, which was set to 100%.
We first looked at whether Vifs obtained from A3G WT/ WT or A3G H186R/H186R patients would differ in their ability to counteract A3G. All patient-derived Vif variants counteracted wild type A3G and A3G-H186R to similar levels, irrespective of the patient's A3G variant (Fig. 2,  compare within a and b, NS, unpaired t test) . This indicates that HIV-1 Vif does not adapt to the different A3G variants in vivo. Western blot analysis showed that the level of A3G degradation (compare with the no Vif control) was similar among Vifs (compare between Fig. 2a  and b ), which is in agreement with the infectivity data. Additionally, we observed that the expression levels of the individual Vif variants was highly variable, but was independent of both the patient's A3G genotype from which they were derived as well as of their activity to degrade and counteract A3G ( Fig. 2a and b) .
Intrinsic antiviral activity of wild type A3G and A3G-H186R
To determine whether the A3G variants differ in the restriction activity, we compared viral infectivity in the presence of wild type A3G or A3G-H186H (compare between Fig. 2a and b) . The infectivity values in the presence of A3G-H186R were always significantly higher compared with wild type A3G (P < 0.0001, paired t test), indicating that A3G-H186R restricts HIV less efficiently than wild type A3G (Fig. 2c) . This difference is likely attributable to the lower basal antiviral activity of A3G-H186R, because the same result is also apparent in the absence of Vif (Fig. 2d, 4 .32 AE 0.21 for wild type A3G versus 6.9 AE 0.28 for A3G-H186R, P ¼ 0.0007, unpaired t test). This small but significant difference suggests that A3G-H186R intrinsically has reduced antiviral activity.
Taken together, we observed no evidence for functional adaptation of Vif to the different A3G variants in vivo. Importantly, our data show that the wild type A3G was more efficient at restricting HIV compared with A3G-H186R variant, which may explain the accelerated HIV-1 disease progression in A3G H186R/H186R patients.
Discussion
Several studies showed that A3G H186R/H186R patients experience accelerated AIDS disease progression compared with individuals expressing A3G WT/WT or A3G WT/H186R [19, [21] [22] [23] . We observed that A3G-H186R restricts HIV-1 less potently than wild type A3G, both in the presence as well as in the absence of Vif. This novel finding indicates that A3G-H186R intrinsically has less antiviral activity, which is in agreement with a previous study which used cell-free biochemical approaches which shows that A3G-H186R has reduced deaminase activity [48] . It is also possible that the H186R substitution may affect its packaging into virions, RNA binding or protein oligomerization, and further mechanistic studies are required to elucidate the reduced antiviral activity of A3G-H186R. We speculate that A3G is not always fully counteracted by Vif in vivo, and that the reduced restriction of A3G-H186R leads to higher viral loads and a more rapid disease progression in patients expressing A3G H186R/H186R .
Studies show that SIV Vif adapts to polymorphisms in A3G [4, 49, 50] . We, therefore, anticipated that Vif would reduce its activity to degrade A3G-H186R because it poses less of a threat than A3G wild type. However, Vif variants from A3G WT/WT or A3G H186R/ H186R showed no differences in activity, indicating that Vif does not adapt to A3G-H186R. It is conceivable that the difference in anti-HIV activity of the A3G variants is too small to create sufficient selective pressure for Vif adaptation, given that A3G-H186R has less antiviral activity than the wild type counterpart.
Together, polymorphisms in multiple APOBEC3 proteins such as A3G and A3H in combination with a HIV strain encoding a specific Vif variant could have profound effects on HIV replication and HIV-disease progression in patients [19, [21] [22] [23] 28, 29, 51] . Indeed, the time to progression to AIDS varies widely in patients, of which only a small percentage could be attributed to natural polymorphisms in genes, commonly associated with differential outcome such as CCR5 or HLA [52] [53] [54] [55] [56] [57] [58] .
